United Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, United Therapeutics sits in the top decile of US sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count).
United Therapeutics: 63 sponsored US clinical trials, 5 recruiting.
United Therapeutics sponsors 63 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 39 completed. 26 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 4 trials.
Top-decile sponsor footprint
United Therapeutics ranks in the top decile of sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
39 of 56 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (69.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
63 total, page 2 of 2
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
NCT00643604
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
NCT00439946
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
NCT01027949
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00325403
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00325442
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
NCT00373360
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
NCT00147199
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
NCT00067041
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
NCT00060996
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
NCT00058929
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
NCT00004497
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 14 |
| Phase 3 | 18 |
| Phase 4 | 8 |
What is open in the United Therapeutics pipeline
5 recruiting of 63 indexed (8% open); 39 completed (62%).
Phase mix: 26 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Pulmonary Arterial Hypertension (4 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
United Therapeutics: open-pipeline peers nationwide
Peers matched on 63 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
United Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 63 trials (± recruiting share)
- Actelion · 63 trials · 0% recruiting
- Hennepin Healthcare Research Institute · 63 trials · 6% recruiting
- University of Oregon · 63 trials · 16% recruiting
- Cephalon · 64 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
Related
What to do with this United Therapeutics page
63 registered trials is a research-attention snapshot, not an endorsement of United Therapeutics or any single study.
- 5 of United Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Arterial Hypertension is the condition United Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
United Therapeutics pipeline card: 63 registered trials from official public datasets.Report a data error.